These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 11792315)
21. Molecular analysis of Duchenne muscular dystrophy: past, present, and future. Davies KE; Tinsley JM; Blake DJ Ann N Y Acad Sci; 1995 Jun; 758():287-96. PubMed ID: 7625698 [No Abstract] [Full Text] [Related]
22. [Lessons of dystrophin]. Desnuelle C Presse Med; 1994 May; 23(19):896-900. PubMed ID: 7937619 [TBL] [Abstract][Full Text] [Related]
23. Half the dystrophin gene is apparently enough for a mild clinical course: confirmation of its potential use for gene therapy. Passos-Bueno MR; Vainzof M; Marie SK; Zatz M Hum Mol Genet; 1994 Jun; 3(6):919-22. PubMed ID: 7951237 [TBL] [Abstract][Full Text] [Related]
24. The childhood muscular dystrophies: making order out of chaos. Tsao CY; Mendell JR Semin Neurol; 1999; 19(1):9-23. PubMed ID: 10711985 [TBL] [Abstract][Full Text] [Related]
25. Long-term correction of mouse dystrophic degeneration by adenovirus-mediated transfer of a minidystrophin gene. Vincent N; Ragot T; Gilgenkrantz H; Couton D; Chafey P; Grégoire A; Briand P; Kaplan JC; Kahn A; Perricaudet M Nat Genet; 1993 Oct; 5(2):130-4. PubMed ID: 8252038 [TBL] [Abstract][Full Text] [Related]
26. Current understanding of dystrophin-related muscular dystrophy and therapeutic challenges ahead. Zhou GQ; Xie HQ; Zhang SZ; Yang ZM Chin Med J (Engl); 2006 Aug; 119(16):1381-91. PubMed ID: 16934185 [TBL] [Abstract][Full Text] [Related]
31. Expression of human full-length and minidystrophin in transgenic mdx mice: implications for gene therapy of Duchenne muscular dystrophy. Wells DJ; Wells KE; Asante EA; Turner G; Sunada Y; Campbell KP; Walsh FS; Dickson G Hum Mol Genet; 1995 Aug; 4(8):1245-50. PubMed ID: 7581360 [TBL] [Abstract][Full Text] [Related]
32. Molecular approaches to therapy for Duchenne and limb-girdle muscular dystrophy. Stedman HH Curr Opin Mol Ther; 2001 Aug; 3(4):350-6. PubMed ID: 11525558 [TBL] [Abstract][Full Text] [Related]
33. [Pathobiogenetic concept of Duchenne muscular dystrophy following the discovery of dystrophin as the deficient protein]. Kunze D; Rüstow B Z Med Lab Diagn; 1991; 32(3-4):141-6. PubMed ID: 1897290 [No Abstract] [Full Text] [Related]
34. Get personal with gene therapy for muscular dystrophy. Rando TA Lancet Neurol; 2008 Mar; 7(3):196-8. PubMed ID: 18275918 [No Abstract] [Full Text] [Related]
35. [Advances in genome editing technologies for treating muscular dystrophy.]. Makita Y; Hozumi H; Hotta A Clin Calcium; 2017; 27(3):391-399. PubMed ID: 28232654 [TBL] [Abstract][Full Text] [Related]
36. Dystrophin gene repair in mdx muscle precursor cells in vitro and in vivo mediated by RNA-DNA chimeric oligonucleotides. Bertoni C; Rando TA Hum Gene Ther; 2002 Apr; 13(6):707-18. PubMed ID: 11936970 [TBL] [Abstract][Full Text] [Related]
37. Recent developments in the biology of dystrophin and related molecules. Karpati G Curr Opin Neurol Neurosurg; 1992 Oct; 5(5):615-21. PubMed ID: 1392135 [TBL] [Abstract][Full Text] [Related]
38. Dystrophin-glycoprotein complex: its role in the molecular pathogenesis of muscular dystrophies. Matsumura K; Campbell KP Muscle Nerve; 1994 Jan; 17(1):2-15. PubMed ID: 8264699 [TBL] [Abstract][Full Text] [Related]